- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
The Stop TB Partnership is governed by a Coordinating Board, supported by two standing board committees: Executive Committee and Finance Committee.
In 2015 declaration “Transforming our world: the 2030 Agenda for Sustainable Development”, Member States pledged to end the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases by 2030, and to combat hepatitis and other communicable diseases. This report reviews progress and challenges in the global response to reduce the burden of these diseases in the context of the Millennium Development Goals, and looks ahead to identify the strategies and approaches that will be needed to accelerate progress during the new development era. The report was developed by WHO’s Cluster for HIV/ AIDS, TB, Malaria and Neglected Tropical Diseases in 2015.
Keywords: health system, 2030 targets, universal health coverage, research and innovation, data, monitoring
This document shares best practices in engagement of health care providers in programmatic management of drug-resistant tuberculosis that have been documented in different countries and regions and implemented by different stakeholders. Case studies presented in the document are lessons learned for scale-up of public-private mix for the management of drug-resistant TB at country level.
Keywords: prevention, control, public sector, private sector, treatment
The framework has two fundamental objectives: 1) To promote, enhance and intensify TB research and innovation at country level, with a focus on low- and middle-income countries, through the development of country-specific TB research plans and strong research capacity. 2) To promote, enhance and catalyse TB research at global level through advocacy, sharing innovations, discussion of global priorities in TB research and development of regional and international networks for research and capacity building.
Engaging all relevant health care providers in the management of DR-TB cases is an important intervention to achieve the goal of universal access to DR−TB care and services. However, only limited progress has been made to date in engaging non-NTP providers in the management of DR-TB patients. WHO/GTB conducted four in-country assessments to Myanmar, Nigeria, Pakistan and Turkey from November 2013 to February 2014. Following the in-country assessments, an "Expert consultation meeting on public-private mix for the management of drug-resistant tuberculosis (PPM DR-TB)", was held in Geneva, Switzerland, 23–24 June 2014. As a result of the assessments and consultation, the "Framework for engagement of all health care providers in the management of drug-resistant tuberculosis" has been developed.
The 2015 revision of a guide to monitoring and evaluation for collaborative TB/HIV activities is developed through close collaboration between the World Health Organization, the United States President’s Emergency Plan for AIDS Relief, the Joint United Nations Programme on HIV and AIDS and the Global Fund to Fight AIDS, Tuberculosis and Malaria and extensive consultations with partners and national programmes. It renews focus on quality of data and its utility for programmatic response. The monitoring indicators are broadly categorized into core indicators for global and national level use and optional indicators. While the core indicators enable monitoring of key TB/HIV interventions as in the past, some are modified to enhance accuracy of data and others to broaden scope.
The Statement of Action is the product of a preceding WHO TB Consultation held in Addis Ababa on 11 to 13 November, 2015. The consultation brought together 90 NGOs and other CSOs, along with national TB programmes and donors, to dialogue and share best practices, innovative approaches, challenges and opportunities in their community-based activities within and beyond TB care and health. The participants explored concrete ways in which they could work together, alongside governments and other partners, to ensure effective implementation of the WHO End TB Strategy. The meeting agenda was also informed by detailed inputs from 400 NGOs and other CSOs who participated in an advance online consultation.
A national situational assessment is very important for the planning and the implementation of PPM DR-TB activities in the respective country. A careful country-specific analysis about the current status of management of DR-TB patients, with a focus on all the various health care providers, will show the way forward towards achieving the goal of universal access to quality diagnosis and treatment for all cases of tuberculosis, including those with DR−TB. A country assessment tool has been designed and field tested in 4 countries.
This tool enables a country or other users to gather the needed data that will serve as a basis for designing a sound plan of expanding DR-TB management, by engaging all relevant care providers. The objective of the assessment tool is to assist countries in moving towards engagement of all relevant health care providers in DR-TB management. The main objective of this tool is to facilitate a comprehensive assessment of a country’s current situation in terms of PPM TB and drug-resistant TB care.
India has had a National Tuberculosis Programme (NTP) since 1962. However, a comprehensive review of the NTP in 1992 found that the NTP had not achieved its aims or targets. Based on the recommendations of the 1992 review, the Revised National Tuberculosis Control Programme (RNTCP), incorporating the components of the internationally recommended DOTS strategy for the control of TB, was developed. RNTCP has now been implemented in the country for more than a decade, and has been expanded geographically to achieve nation-wide coverage in March 2006. The spread of human immuno-deficiency virus (HIV) during the last two decades, emergence of various forms of drug resistant TB and vast and unregulated private sector pose additional challenges in effective TB control.
Keywords: HIV, TB, diagnosis, treatment, prevention
In 2011 WHO conditionally recommended the use of at least 36 months of isoniazid preventive therapy (IPT) (as a proxy for lifelong or continuous treatment) for people living with HIV in high TB-prevalence and transmission settings. The evidence of the benefits and harms of 36-month IPT compared to 6-month IPT was reassessed and the following recommendation was made: “In resource-constrained settings with high TB incidence and transmission, adults and adolescents living with HIV, who have an unknown or positive tuberculin skin test (TST) status and among whom active TB disease has been safely ruled out, should receive at least 36 months of IPT. IPT should be given to such individuals regardless of whether or not they are receiving ART. IPT should also be given irrespective of the degree of immunosuppression, history of previous TB treatment, and pregnancy.” The quality of evidence was rated as low. The conditionality of the recommendation was primarily due to the fact that implementation of continuous IPT requires considerations of TB epidemiology, health infrastructure, programmatic priorities and patient adherence.
Keywords: TB, HIV, prevention, control, diagnosis, adults and adolescents